Treatments for HER2 Positive Metastatic Breast Cancer: Past, Present, and Future
|
|
- May Freeman
- 8 years ago
- Views:
Transcription
1 Treatments for HER2 Positive Metastatic Breast Cancer: Past, Present, and Future Maria Theodoulou, MD Attending, Breast Cancer Service,MSKCC Professor of Medicine Weill Cornell Medical School
2 Outline 1. Biology of HER2 2. Sequencing of HER2 therapies for MBC Key clinical trials Sequential use in 1 st, 2 nd,3 rd line and beyond Current 2015 treatment algorithm 3. Future Therapies in Development
3 Breast Cancer Epidemiology Over 1 million estimated new cases of invasive breast cancer diagnosed annually worldwide The human epidermal growth factor receptor (HER2) is amplified and overexpressed in ~20-25% of breast cancers Distinct gene expression pattern: differs from basal- and luminal-like breast cancer subgroups Up to half of HER2-positive tumors are ERpositive Approximately 60%-75% of patients with HER2-positive tumors are node-positive Of patients with HER2-positive disease Approximately one third are between 50 and 59 years old Approximately one sixth are 60 years old Over 60% of patients with HER2-positive disease present with high-grade tumors Luminal Subtype A Luminal Subtype B ERBB2+ Basal Subtype Normal Breast like HER2 gene cluster American Cancer Society. Cancer Facts and Figures Cobleigh et al. J Clin Oncol. 1999;17:2639. Pegram et al. Cancer Treat Res. 2000;103:57. Piccart-Gebhart et al. N Engl J Med. 2005;353:1659. Slamon et al. 29th Annual San Antonio Breast Cancer Symposium. Abstract 52 and oral presentation. Sorlie et al. Proc Natl Acad Sci U S A. 2003;100:
4 The HER Family of Receptors Ligands TGF-α EGF Epiregulin Betacellulin HB-EGF Amphiregulin ORPHAN Heregulin Heregulin (neuregulin-1) Epiregulin HB-EGF Neuregulins-3, -4 HER1 HER2 HER3 HER4 PI3K Ras PTEN Raf AKT MEK MAPK Survival Cyclin D Proliferation
5 Normal HER2 Expression Normal (~ 20,000-50,000 receptors) HER2 receptor HER2 gene HER2 mrna Pegram et al. Cancer Treat Res. 2000;103:57.
6 Amplified and Overexpressed HER2 HER2-positive (Up to 2 million receptor molecules) HER2 receptor HER2 gene HER2 mrna Amplification: an abnormal increase in the HER2 gene copy number Overexpression: an abnormal increase in the number of HER2 protein receptors Pegram et al. Cancer Treat Res. 2000;103:57.
7 Disease-free survival probability Percentage survival 1 Disease-Free and Overall Survival in Pts With Breast Cancer Based on HER Not amplified (n=52) HER2 (n=ns) Amplified (n=11) >5 copies HER2+ (n=50) 0 P= Years 0 P< Years NS = not specified. Slamon et al. Science. 1987;235:177; Witton et al. J Pathol. 2003;200:290.
8 Trastuzumab: Mechanisms of Action HER2 1. Inhibition of receptor-receptor interactions Inhibition of phosphorylation and downstream signaling cascades Induction of apoptosis 2. Receptor-antibody complex internalization decreases protein on cell surface 3. Immune activation Complement-mediated cytotoxicity Antibody-dependent cellular cytotoxicity signaling
9
10 Survival (%) Trastuzumab Added to Chemotherapy Improves OS in MBC No. At Risk Chemotherapy plus trastuzumab Chemotherapy alone vs 20.3 mo p = 0.01 Chemotherapy plus trastuzumab Months After Enrollment Chemotherapy alone Slamon, NEJM 2001
11 Lapatinib Mechanism of Action Binds to intracellular ATP binding site of EGFR (ErbB-1) and HER2 (ErbB-2) preventing phosphorylation and activation HER2 HER1 Blocks downstream signaling through homodimers and heterodimers of EGFR (ErbB-1) and HER2 (ErbB-2) TK TK Dual blockade of signaling may be more effective than the single-target inhibition provided by agents such as trastuzumab Downstream signaling cascade Rusnak et al. Mol Cancer Ther 2001;1:85-94; Xia et al. Oncogene 2002;21: ; Konecny et al. Cancer Res. 2006;66:
12 PHASE III: Lapatinib + Capecitabine vs Capecitabine HER2+ LABC or MBC with prior exposure to an anthracycline, a taxane and trastuzumab* N=528 R A N D O M I Z E Lapatinib 1250 mg po qd continuously + Capecitabine 2000 mg/m 2 /d po days 1-14 q 3 wk Capecitabine 2500 mg/m 2 /d po days 1-14 q 3 wk Patients on treatment until progression or unacceptable toxicity, then followed for survival *Trastuzumab must have been administered for metastatic disease Geyer et al N Engl J Med Dec 28;355(26):
13 % of Patients Progression-Free Time to Progression (ITT) Lapatinib and Capecitabine Capecitabine No. of patients Median TTP (mo) Hazard ratio (95% CI) 0.49 ( ) P value (log-rank) < Weeks TTP = time to progression. Geyer CE, et al. N Engl J Med. 2006;355:
14 Capecitabine With or Without Lapatinib: Study Results Capecitabine n = 201 Lapatinib and Capecitabine n = 198 Hazard Ratio (95% CI) P Value Median time to progression (mo) ( ) Median progression-free survival 2 (mo) ( ) <0.001 Overall response rate (%) (CR + PR) Overall survival 1 (%) ( ) CR = complete response; PR = partial response. 1 Geyer CE, et al. Br Cancer Res Treat, Geyer CE, et al. N Engl J Med. 2006;355:
15 Clinical Pathway: HER2 Positive MBC, st Line Taxane + Trastuzumab 2 nd Line Lapatinib + capecitabine?
16 Paradigm Shift: Continuing Trastuzumab After Progression HER2+ MBC with progression during or after a treatment with trastuzumab ± CT as adjuvant or first-line therapy a Primary end point: TTP R Capecitabine + Trastuzumab (n =78) 2500 mg/m2 on days 1-14, q21d + trastuzumab 6 mg/kg q3w Capecitabine (n=78) 2500 mg/m2 on days 1-14, q21d a Between 01/04 and 05/07, 156 of 482 planned patients were randomized. von Minckwitz G et al, J Clin Oncol 2009;27(12):1935-7
17 PFS C T OS C T C C+T P-value RR 27% 48% CB 54% 75.3% TTP 5.6m 8.2 m OS 20.4m 25.5m 0.26 Continuing trastuzumab beyond progression improves efficacy of 2 nd line chemotherapy C- capecitabine T- trastuzumab von Minckwitz G et al, J Clin Oncol 2009;27(12):1935-7
18 Phase 2 Trials of Chemotherapy Plus Trastuzumab: Response Rates Single Agent Chemo Authors RR(%) docetaxel Marty et al 61% Esteva et al 70% Vinorelbine Burstein et al 42% Jahanzeb et al 78% Capecitabine Bangemann et al 56% Liposomal doxorubicin Theodoulou et al 58% Chia et al 52% Gemcitabine O Shaughnessy et al 38% Cisplatin Pegram & Slamon 24% Combinations Paclitaxel + Carboplatin Robert et al 52% Paclitaxel + Gemcitabine Sledge et al 67% Paclitaxel + Doxorubicin Bianchi et al 88% Docetaxel + Cisplatin Pegram et al 79% Docetaxel + Carboplatin Pegram et al 58% Gemcitabine + Cisplatin Heinemann et al. 43% Gemcitabine + Carboplatin Yardley et al 66%
19 Preclinical Synergy Of Lapatinib + Trastuzumab In HER2+ Tumor Xenografts Greater antitumor activity with T+ L compared to either T or L alone Scaltriti et al. Oncogene 2009
20 Dual HER2 Blockade Improves Clinical Outcome HER2+ MBC (IHC 3+/ FISH+); Progression on anthracycline, taxane or trastuzumab; progression on most recent trastuzumab regimen R Lapatinib 1500 mg/d PO (n=148) Lapatinib 1000 mg/d PO Trastuzumab 4 2 mg/kg IV qw (n=148) Crossover allowed after 4 wk therapy n=73 End points Primary: PFS in ITT population Secondary: OS; ORR; CBR; DR; TTR; safety; QoL a 2 pts had >1 event b 3 pts recovered while remaining on treatment c Cardiac failure; cause of death: pulmonary thromboembolism Blackwell K et al JCO
21 Cumulative % Alive without Progression Progression-Free Survival: Lapatinib vs Lapatinib + Trastuzumab Subjects At Risk L 148 L+T % % L N = 145 L+T N = 146 Progressed or Died, n Median PFS, wks Hazard ratio (95% CI) 0.73 (0.57, 0.93) P value Median OS, mo Hazard ratio 0.74 (0.57, 0.97) P value Mo PFS Time from Randomization (wks) Blackwell K et al, JCO 2010; Blackwell K et al., J Clin Oncol 2012
22 22 Clinical Implications Continued HER2 blockade beyond trastuzumab progression achieves better outcomes Capecitabine + Trastuzumab > Capecitabine Capecitabine + Lapatinib > Capecitabine Continuation of trastuzumab itself beyond progression is effective HER2 targeted therapy Dual targeting of HER2 without chemotherapy results in substantial efficacy in trastuzumab pretreated patients in the MBC setting Trastuzumab +Lapatinib > Lapatinib
23 Clinical Pathway: HER2 Positive MBC, st Line Taxane + Trastuzumab 2 nd Line and beyond Lapatinib + capecitabine Trastuzmab+ capecitabine Trastuzumab+ Lapatinib Trastuzumab + Chemo
24 Pertuzumab and Trastuzumab: Complementary Mechanisms of Action HER2 HER 1/3/4 Trastuzumab Pertuzumab Subdomain IV Dimerization domain Trastuzumab: Inhibits ligand-independent HER2 signaling Activates ADCC Prevents HER2 ECD shedding Pertuzumab: Inhibits ligand-dependent HER2 dimerization and signaling Activates ADCC Baselga J, et al. Presented at: 34th Annual San Antonio Breast Cancer Symposium; December 6-11, 2011; San Antonio, TX. Abstract S5-5; Baselga J, et al. J Clin Oncol. 2010;28(7):
25 CLEOPATRA study design n=406 Trastuzumab + Placebo PD Patients with HER2-positive MBC centrally confirmed (N=808) 1:1 Docetaxel 6 cycles recommended Trastuzumab + Pertuzumab PD n=402 Docetaxel 6 cycles recommended Randomization was stratified by geographic region and prior treatment status (neo/adjuvant chemotherapy received or not) HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; PD, progressive disease Baselga et al, NEJM 2012
26
27 OS (%) Final OS Analysis Median follow-up 50 months (range 0 70 months) n at risk Ptz + T + D Pla + T + D HR % CI = 0.56, 0.84 p = Time (months) months Δ 15.7 months Ptz + T + D Pla + T + D 56.5 months ITT population. Stratified by geographic region and neo/adjuvant chemotherapy. CI, confidence interval; Pla, placebo; Ptz, pertuzumab. Swain et al
28 Conclusion CLEOPATRA demonstrated a statistically significant improvement in PFS and OS. Acceptable safety signals Docetaxel + Tratuzumab + Pertuzumab is now a standard of care for patients with HER2+ MBC in the first-line setting
29 Phase II Study: Paclitaxel + Trastuzumab + Pertuzumab for HER2+ MBC N = 69 HER prior Rx 1 endpoint=6 mo PFS q week q 3 weeks. Paclitaxel at 80 mg/m 2 q 3 weeks. every 4 cycles.. cardiac biomarkers every 2 cycles. Pertuzumab at 840mg load 420 mg q 3 w Trastuzumab at 8 mg/kg load 6 mg/kg q 3 w ECHO w/ strain imaging N Iyengar, Rebecca Rohrer, Melanie Chen, Erinn Bacchus, Angemael Syldor, Nicola Hamilton, Dang et al, JCO 2015
30 Paclitaxel+ Tratuzumab+ Pertuzumab: Response
31 Primary Endpoint: 6-month PFS Very well tolerated No febrile neutropenia
32 NCCN /ASCO GUIDELINES: HER2+ MBC Preferred 1 st -line Rx: Docetaxel + HP (CLEOPATRA study) Paclitaxel + HP (MSKCC study) Giordano et al, JCO 2014; NCCN v.3, 2013
33 Clinical Pathway: HER2 Positive MBC, st Line Taxane + Trastuzumab + Pertuzumab 2 nd Line and beyond Lapatinib + capecitabine Trastuzmab+ capecitabine Trastuzumab+ Lapatinib Trastuzumab + Chemo
34 Ado Trastuzumab Emtansine (T-DM1) Antibody-conjugate Binds to HER2 with affinity similar to trastuzumab Provides intracellular delivery of mertansine Derivative of maytansine, a natural-product microtubule polymerization inhibitor more potent than vincristine Phase 1 Trial: 34% RR Ben Nulsen, Nicola Hamilton, Modi et al
35 EMILIA Study Design HER2+ (central) LABC or MBC (N=980) T-DM1 3.6 mg/kg q3w IV PD Prior taxane and trastuzumab Progression on metastatic tx or within 6 mos of adjuvant tx 1:1 Capecitabine 1000 mg/m 2 orally bid, days 1 14, q3w + Lapatinib 1250 mg/day orally qd PD Stratification factors: World region, number of prior chemo regimens for MBC or unresectable LABC, presence of visceral disease Primary end points: PFS by independent review, OS, and safety Key secondary end points: PFS by investigator, ORR, duration of response, time to symptom progression Blackwell et al, Plenary Verma S et al, NEJM 2012
36 Proportion progression-free Progression-Free Survival by Independent Review Median (mos) No. events Cap + Lap T-DM Stratified HR=0.650 (95% CI, 0.55, 0.77) P< Time (mos) No. at risk by independent review: Cap + Lap T-DM Unstratified HR=0.66 (P<0.0001). Verma S et al, NEJM 2012
37 Overall Survival Verma S et al, NEJM 2012
38 EMILIA: Conclusion T-DM1 demonstrated improved efficacy over cape + lapatinib: PFS(HR=0.65; P<0.001) OS (HR=0.68; P<0.001) Safety and secondary end points favored T-DM1 T-DM1 is an effective option for HER2-positive metastatic breast cancer
39 Clinical Pathway: HER2 Positive MBC, st Line Taxane + Trastuzumab+ Pertuzumab 2 nd Line Ado Trastuzumab Emtansine (T-DM1) 3 rd Line and beyond Lapatinib + capecitabine Trastuzmab+ capecitabine Trastuzumab+ Lapatinib Trastuzumab + Chemo
40 Phase III T-DM1 1 st line Trial: MARIANNE Taxane + Trastuzumab N=1092 HER2+ MBC First-line TDM1 TDM1+ Pertuzumab 1 Endpoint: PFS 2 Endpoints: OS, TTF, DOR, ORR, CBR T= paclitaxel 80 m/m weekly or docetaxel at m/m q 3 w H=trastuzumab 2 mg/kg q w or 6 mg/kg q 3 w P=pertuzumab at 840 mg load 420mg q 3 w TDM= trastuzumab/dm1 at 3.6 mg/kg q 3 w
41 Clinical Pathway: HER2 Positive MBC, 2015 HER2+ MBC ER- *ER+ Taxane/trastuzumab/pertuzumab Ado Trastuzumab Emtansine (T-DM1) Letrozole +/- lapatinib AI or tamoxifen +/- trastuzumab ER- guidelines Lapatinib/capecitabine Trastuzumab/capecitabine Trastuzumab/lapatinib Trastuzumab/chemotherapy T-DM1 if not received earlier Pertuzumab if not received earlier *No OS advantage with hormone therapy plus anti-her2 therapy Giordano et al. JCO 2014 (ASCO GUIDELINES)
42 Timeline of HER2 Therapy for HER2+ MBC 1980 s Discovery of erbb2 as an oncogenic driver of breast cancer Trastuzumab 1 st line Rx of HER2+ MBC with paclitaxel; monotherapy Trastuzumab approved for adjuvant Rx Of NP+ BC Lapatinib approved for 2 nd line Rx of MBC with capecitabine Pertuzumab approval for 1 st line Rx of MBC with paclitaxel and trastuzumab Trastuzumab approved for adjuvant Rx of high risk NN- BC Ado Trastuzumab Emtansine (T-DM1) approval for 2 nd line Rx of MBC Pertuzumab Approval for neoadjuvant BC
43 FUTURE 43
44 HER2 Therapies in Metastatic BC LJM716 R MM-302 BYL719 afatinib GDC-0032 MMK206 Gajria et al. Exp Rev Anticancer Ther 2011
45 BOLERO-3: Study Design N = 572* Locally advanced or metastatic HER2 + breast cancer Prior taxane required TRAS resistance Adjuvant: progression on or within 12 months of TRAS Metastatic: progression within 4 weeks of TRAS Measurable disease only Randomize 1:1 Stratification by prior lapatinib use (yes/no) Everolimus (5 mg PO daily) + Vinorelbine (25 mg/m 2 weekly) + TRAS (2 mg/kg week ) (n = 284) Placebo (PO daily) + Vinorelbine (25 mg/m 2 weekly) + TRAS (2 mg/kg weekly*) (n = 285) Therapy until PD or intolerable toxicity Endpoints: Primary: PFS Secondary: OS, ORR, time to deterioration of ECOG PS, safety, DoR, CBR, and QoL * Actual enrollment was 569. Following a 4-mg/kg loading dose on day 1, cycle 1 (1 cycle = every 21 days). Abbreviations: CBR, clinical benefit rate; DoR, Duration of response; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; ORR, overall response rate; OS overall survival; PD, progressive disease; PFS, progressive-free survival; PO, oral; PS, performance status; QoL, quality of life O Regan et al, ASCO 2013
46 Probability, % BOLERO-3: Primary Endpoint Progression-Free Survival by Local Assessment Hazard ratio = 0.78; 95% CI [0.65, 0.95] Log-rank P value =.0067 Median PFS Everolimus: 7.00 months; 95% CI [6.74, 8.18] Placebo: 5.78 months; 95% CI [5.49, 6.90] Censoring times Everolimus (n/n = 196/284) Placebo (n/n = 219/285) 0 Number of Patients Still at Risk Everolimus Placebo Abbreviations: CI, confidence interval Time, weeks Interim OS data not mature O Regan et al, ASCO
47 BOLERO-3: Most Common Adverse Events (Nonhematologic) Everolimus Arm (N = 280) Placebo Arm (N = 282) Adverse Event, % All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4 Stomatitis Fatigue < Pyrexia Diarrhea Nausea Decreased appetite Constipation 30 < <1 0 Rash Hyperglycemia* Noninfectious pneumonitis* 6 <1 <1 3 1 <1 Hyperlipidemia* * Included as adverse events of interest despite lower frequency. 47 O Regan et al, ASCO 2013
48 BOLERO-3: Summary Addition of everolimus to trastuzumab + vinorelbine significantly prolongs PFS by 1.2 mo (p = ) Adverse events consistent with previous experience with everolimus Interim OS data are not yet mature PROOF OF CONCEPT THAT BLOCKING THE PATHWAY - NOT THE RECEPTOR - IS AN EFFECTIVE ANTI-CANCER STRATEGY FOR HER2+ BC 48
49 Mechanisms of activation of the PI3K-AKT-mTOR pathway RTK signaling & activating mutations Neuregulin HER2 amplification ~15-20% BrCa HER2 HER3 PI3K PI3KCA mutation ~ 25-30% AKT1 mutation ~1-5% BrCa AKT PTEN Loss of PTEN ~15-20% BrCa Cell size translation Courtesy of S. Chandarlapaty mtor Proliferation Survival Invasion -p85-pi3k mutation -Loss of INPP4B -PDK1 amplification -Overexpression of HER3/IGF1R/EGFR - Phlpp loss
50 Phase 1 Trial: LJM716+BYL719+Trastuzumab Payal Shah, Stephen Zamora, Valentina Sterlin, Joe Gonzalez et al 2014
51 HER2 Therapies in Metastatic BC LJM716 R MM-302 BYL719 afatinib GDC-0032 MMK206 Gajria et al. Exp Rev Anticancer Ther 2011
52 17AAG Inhibition of HER2+ SKBr-3 Cells HER2 is one of the most sensitive clients Control 17-AAG x 24 h P. Munster, personal communication
53 Phase 2 Trial of 17-AAG plus Trastuzumab: Best Response (n=25) % change from baseline Response Code Progressive Disease Stable Disease Partial Response Modi et al, Clin Cancer Res, 2011
54 HSP90 Inhibitor Compounds in Clinical Development HSP90 INHIBITOR COMPANY PHASE TUMOR TYPE Geldanamycin Derivatives Tanespimycin (17-AAG) Kosan Biosciences/ Britstol Myers Squibb II III Breast, renal, thyroid, ovarian, lymphoma, leukemia Multiple Myeloma Retaspimycin (IPI-504) Infinity Pharmaceuticals II III NSCLC, liposarcoma, Breast (HER2+) GIST (closed) Alvespimycin (17-DMAG) Synthetic Inhibitors Kosan Biosciences/ Bristol Myers Squibb CNF2024 (BIIB021) Biogen Idec I II I Solid tumors, refractory leukemias Breast (HER2+), solid tumors GIST NVP-AUY922 Novartis II Breast, solid tumors, multiple myeloma SNX-5422 Esanex Inc I Solid tumors, hematological malignancies, HER2+ cancers STA-9090 (Ganetespib) Synta Pharmaceuticals I/II/III Solid tumors, hematological malignancies, HER2+ breast cancer PU-H71 MSKCC/ NCI I Solid tumors, triple negative breast cancer AT NCI I/II Solid tumors, prostate DS 2248 Daiichi Sankyo Inc I Solid tumors XL 888 Exelixis Inc I Solid tumors Debio 0932 DebioPharm SA I Solid tumors
55 Phase 1 Trial of HSP90 Inhibition in HER2+ MBC TAXOL TRASTUZUMAB GANETESPIB DEFINE MTD EVALUATE SAFETY AMEND TO FIRST LINE SETTING IN COMBINATION WITH PERTUZUMAB Komal Jhaveri, Tara O Neill, Deirdre Neville, et al
56 Summary HER2 Targeted Therapy has transformed the lives of many patients Use new agents for HER2+ MBC in sequence Trastuzumab Pertuzumab - T-DM1 Lapatinib Biomarkers under development Advancing promising agents into the early stage setting
57 Inflammation & Cancer Coussens & Werb. Nature 2002.
58 Inflammation: the 7 th Hallmark Mantovani. Nature 2009.
59 Obesity Causes an Inflammatory State Olfefsky & Glass. Annu Rev Physiol 2010.
60 Obesity Associated Diseases Iyengar et al. Cancer Tongue Kanneganti & Dixit. Nature Immunol 2012.
61 Obesity & Cancer: Mechanisms
62 Inflammation & Aromatase Activity Howe et al. Clin Cancer Res Morris et al. Cancer Prev Res 2011.
63 Clinical Characteristics of Patients by Characteristic Age, years CLS-B Status All Patients (n=237) Patients without CLS-B (n=115) Patients with CLS-B (n=122) Median (range) 48 (22 90) 47 (25 90) 49 (22 80) 0.38 Race, n (%) BMI Asian 14 (6.0%) 7 (6.1%) 7 (5.8%) Black 17 (7.3%) 6 (5.3%) 11 (9.2%) White 203 (86.8%) 101 (88.6%) 102 (85.0%) 0.55 Median (range) 25.3 ( ) 23.1 ( ) 28.3 ( ) <0.001 Menopausal status, n (%) Pre 144 (60.8%) 80 (69.6%) 64 (52.5%) Post 93 (39.2%) 35 (30.4%) 58 (47.5%) Hypertension, n (%) No 201 (84.8%) 102 (88.7%) 99 (81.2%) Yes 36 (15.2%) 13 (11.3%) 23 (18.9%) 0.15 Diabetes, n (%) No 227 (95.8%) 112 (97.4%) 115 (94.3%) Yes 10 (4.2%) 3 (2.6%) 7 (5.7%) 0.34 Iyengar et al. Cancer Prev Res P
64 Clinical Characteristics of Patients by Characteristic Severity of Breast WATi Breast WAT Inflammation None (n=115) Mild (n=59) Severe (n=59) P Age, years Median (range) 47 (25 90) 46 (22 72) 50 (27 80) 0.15 Race, n (%) BMI Asian 7 (6.1%) 3 (5.3%) 4 (6.8%) Black 6 (5.3%) 1 (1.8%) 9 (15.3%) White 101 (88.6%) 53 (93.0%) 46 (78.0%) 0.07 Median (range) 23.1 ( ) 26.0 ( ) 29.8 ( ) <0.001 Menopausal Status, n (%) Pre 80 (69.6%) 39 (66.1%) 22 (37.3%) Post 35 (30.4%) 20 (33.9%) 37 (62.7%) <0.001 Hypertension, n (%) No 102 (88.7%) 52 (88.1%) 44 (74.6%) Yes 13 (11.3%) 7 (11.9%) 15 (25.4%) <0.05 Diabetes, n (%) No 112 (97.4%) 58 (98.3%) 53 (89.8%) Yes 3 (2.6%) 1 (1.7%) 6 (10.2%) 0.05 Iyengar et al. Cancer Prev Res 2015.
65 % CLS-B+ Cases % Cases with severe inflammation % CLS-B+ Cases % CLS-B+ Cases WATi is more common and more severe in obese CB and postmenopausal DC women % cases with CLS-B P<0.001 P< /73 40/116 43/48 % cases with CLS-B P=0.008 P= /93 64/144 D E % cases with CLS-B < Lean Ow 30 Ob P<0.001 P< /83 < Lean 25 Pre Pre 13/33 < Lean 25 Post BMI 37/61 Ow 25 Ob Pre BMI Menopausal Status 45/60 Ow 25 Ob Post E F % cases with severe inflammation P=0.003 P= /27 Lean < 25 Pre 7/13 Premenopause Postmenopause 16/37 30/45 Lean < 25 OwOb 25 Post Pre BMI Menopausal Status OwOb 25 Post Iyengar et al. Cancer Prev Res 2015.
66 Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipocyte size (µ) Mean adipo A C Average adipocyte size ( ) Average adipocyte size ( ) Adipocyte size correlates with BMI and 60 WATi, and is larger in postmenopausal and obese women BMI rho=0.63, P<0.001 ρ=0.63, P< P< A Average adipocyte size ( ) rho=0.63, P<0.001 ρ=0.63, P< CLS-B CLS-B + BMI BMI C Average adipocyte size ( ) 0 None Mild Severe 0 None Mild Severe Inflammation Inflammation E 120 P< Iyengar et al. Cancer Prev Res B Average adipocyte size ( ) D Average adipocyte size ( ) 120 P< P=0.002 P= B Average adipocyte size ( ) D Average adipocyte size ( ) 120 P< CLS-B - CLS-B P=0.002 P= Premenopause Pre menopause Post Post- Menopausal Status Premenopause Pre menopause Post Post- Menopausal Status C Average adipocyte size ( ) Average ad 80 CLS-B CLS-B + - E Average adipocyte size ( ) 120 P< P< None Mild Severe Inflammation < 25 Lean Pre Pre < Lean OwOb Post Pre Post Pre BMI Menopausal Status 25 OwOb Post Post
67 Inflammation Occurs Consistently between Adipose Depots Sites CLS Absent at Both Sites CLS Present at Both Sites Discordant CLS Status P Left versus Right breast Breast versus Abdomen Patients, n (%) 17 (27.0%) 32 (50.8%) 14 (22.2%) CLS/cm 2 Median (range) 0.6 ( ) 0.2 ( ) <0.001 Patients, n (%) 3 (23.1%) 7 (53.8%) 3 (23.1%) CLS/cm 2 Median (range) 1.5 ( ) 0.3 ( ) 0.12 Iyengar et al. Cancer Prev Res 2015.
68 Conclusions WATi occurs in most obese/overweight individuals Postmenopausal state is independently associated with presence & severity of WATi WATi occurs across adipose depots
69 Thank You!
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationSeconda linea di trattamento
XVIII Congresso Nazionale CIPOMO Roma, Giugno 2013 Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Seconda linea di trattamento Giorgio
More informationQu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles
Qu avons-nous appris du développement des anti-her2? Ahmad Awada MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles FOM Lille 2013 1 Her2 breast cancer expression = Poor
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico
ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico Sequenza ottimale del trattamento Maria Teresa Scognamiglio U.O.C. Clinica Oncologica Chieti-Ortona Chieti 12 novembre 213
More informationNovel Targets in Breast Cancer. Vandana Abramson, MD May 1, 2010
Novel Targets in Breast Cancer Vandana Abramson, MD May 1, 2010 Disclosure Information I have no financial relationships to disclose relevant to the content of this presentation. Breast ca: many diseases
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationOptimizing Anti-HER2 Therapy in Advanced Breast Cancer: Integrating New Data and Agents Into Practice
Optimizing Anti-HER2 Therapy in Advanced Breast Cancer: Integrating New Data and Agents Into Practice Learning Objectives Discuss recent clinical trials showing survival advantages in the treatment of
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationBreast Cancer: Background
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of August 2014. All materials contained herein reflect the views of the faculty, and not those
More informationTargeted Therapy in an Era of Genomic Medicine. George W. Sledge MD Stanford University
Targeted Therapy in an Era of Genomic Medicine George W. Sledge MD Stanford University Why Do Women Die of Breast Cancer? Bad biology Avoidable deaths Important subsets of breast cancers defined by molecular
More informationNew Agents as Options in the Treatment of Breast Cancer in 2012 2013. Realities and Possibilities
New Agents as Options in the Treatment of Breast Cancer in 2012 2013. Realities and Possibilities Peter M. Ravdin, MD, PhD UT Health Science Center San Antonio San Antonio, TX 2012 2013 New Options for
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationNew Treatment Paradigms in the Management of Metastatic Breast Cancer. Objectives
New Treatment Paradigms in the Management of Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Assistant Professor of Medicine Director, Breast Oncology Program, UCLA Co-Director, Outpatient Oncology
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationAdjuvant Therapy with Trastuzumab
Adjuvant Therapy with Trastuzumab Hiroji Iwata, M.D. Department of Breast Oncology, Aichi Cancer Center Hospital Although this presentation includes information regarding pharmaceuticals (including products
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationNew Approval Mechanism for Breast Cancer using pathologic Complete Response
New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationWhat s New With HER2?
What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston
More informationThe benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer a systematic review
Mendes et al. Breast Cancer Research (2015) 17:140 DOI 10.1186/s13058-015-0648-2 RESEARCH ARTICLE The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast
More informationNew developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough?
New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough? F. Cardoso, MD Champalimaud Cancer Center Lisbon, Portugal BBM 2010 Thank you to A Tutt & PRIME Oncology
More informationGilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University
Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University Assoc. Editor ASCO University and JGO Progress Against
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More informationPI3K signaling pathway a new target for breast cancer treatment
PI3K signaling pathway a new target for breast cancer treatment Introduction At the 37 th annual San Antonio Breast Cancer Symposium, SABCS, a number of interesting research trends, novelties as well as
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationA Phase 1 Study of MM-302, a HER2- targeted PEGylated liposomal doxorubicin, in Patients with HER2-positive Metastatic Breast Cancer (MBC)
A Phase 1 Study of MM-32, a HER2- targeted PEGylated liposomal doxorubicin, in Patients with HER2-positive Metastatic Breast Cancer (MBC) P LoRusso 1, I Krop 2, K Miller 3, C Ma 4, BA Siegel 4, AF Shields
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationUpdate on neoadjuvant treatment of breast cancer
Update on neoadjuvant treatment of breast cancer «IS PATHOLOGIC COMPLETE RESPONSE STILL A GOOD SURROGATE OF SURVIVAL?» Complete histological response varies according to tumoral type pcr (%) 40 35 30 25
More informationSAMO FoROMe Post-ESMO 2013 Breast Cancer
SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationI. THE IMPORTANCE OF HER2 IN BREAST CANCER
I. THE IMPORTANCE OF HER2 IN BREAST CANCER The human epidermal growth factor receptors (HER), also known as ERBB receptors, are a family of signal transduction proteins. There are 4 family members in humans
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
More informationHOW FAR WE VE COME: TREATING HER2- POSITIVE BREAST CANCER WITH TARGETED THERAPIES
HOW FAR WE VE COME: TREATING HER2- POSITIVE BREAST CANCER WITH TARGETED THERAPIES Javier Cortes, Vall d Hebron Institute of Oncology (VHIO), Medica Scientia Innovation Research (MedSIR) Barcelona, Spain
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationProgress in Treating Advanced Triple Negative Breast Cancer
Progress in Treating Advanced Triple Negative Breast Cancer Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Triple Negative Breast Cancer by Subtype
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationHER2-positive Metastatic Breast Cancer: New Agents on the Horizon
Hong Kong J Radiol. 2012;15(Suppl):S51-6 REVIEW ARTICLE HER2-positive Metastatic Breast Cancer: New Agents on the Horizon W Yeo Department of Clinical Oncology, The Chinese University of Hong Kong, Prince
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationCurr Oncol, Vol. 22, pp. S19-28; doi: http://dx.doi.org/10.3747/co.22.2363 TARGETED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER REVIEW ARTICLE
Curr Oncol, Vol. 22, pp. S19-28; doi: http://dx.doi.org/10.3747/co.22.2363 TARGETED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER REVIEW ARTICLE Targeted therapy in her2-positive metastatic breast
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationInflammatory Breast Cancer: A Unique Pathologic Entity?
Inflammatory Breast Cancer: A Unique Pathologic Entity? Sandra M. Swain, M.D. Director, Washington Cancer Institute Washington Hospital Center Washington DC Outline Overview Therapy High dose chemotherapy
More informationTreatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
More informationManagement of Locally Advanced and Metastatic HER2-Positive Breast Cancer
Management of Locally Advanced and Metastatic HER2-Positive Breast Cancer Pretest Question #1 Which of the following is an antibody-drug conjugate indicated for use in HER2-positive metastatic breast cancer?
More informationLondon Cancer New Drugs Group APC/DTC Briefing
London Cancer New Drugs Group APC/DTC Briefing Continued use of trastuzumab following disease progression in metastatic breast cancer Contents Summary 1 Background 2 Adverse events/safety issues Health
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationLa biologia molecolare «driver» delle scelte terapeutiche: k mammario HER2+
La biologia molecolare «driver» delle scelte terapeutiche: k mammario HER2+ Dr.ssa Lucia Del Mastro U.O. Sviluppo Terapie Innovative IRCCS AOU San Martino-IST Verona, 18 settembre 2015 Copyright 2014 -
More informationThe current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment
The current treatment landscape for early breast cancer: Advances in cytotoxic and endocrine treatment Ahmad Awada, MD, PhD Head of Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles
More informationSymposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive
More informationLa Terapia Personalizzata in Oncologia
AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA La Terapia Personalizzata in Oncologia Roma, 25-26 Ottobre 2011 Stato dell arte e prospettive della Target Therapy nei tumori mammari PierFranco Conte Department
More informationJennifer Diamond M.D. Assistant Professor Developmental Therapeutics and Breast Oncology University of Colorado Anschutz Medical Campus SUMO Fall
Jennifer Diamond M.D. Assistant Professor Developmental Therapeutics and Breast Oncology University of Colorado Anschutz Medical Campus SUMO Fall Meeting September 26, 2015 To understand the biology and
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationPARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center
PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center Poly (ADP-ribose) Polymerase (PARP): Mechanism of Action PARPs: family of enzymes that repair
More informationMonoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationPast, Present and Future HER2 targeted therapy in breast cancer
Past, Present and Future HER2 targeted therapy in breast cancer Joseph Gligorov MD, PhD Tenon Hospital, University Cancer Institute, Paris VI, Sorbonne University Paris, France Disclosures Roche GSK What
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationCLINICAL POLICY Department: Medical Management Document Name: HER2 Breast Cancer Treatments
Page: 1 of 11 Specialist Review: Revised: 06/13 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review
More informationTriple negative Breast Cancer Patient
Triple negative Breast Cancer Patient Alison L Jones November 2013 Mrs Trisha Negative Aged 52) Diagnosed November 2001 T2 N1 (2/11)M0 Left breast. No family history WLE/ANC then FEC/T + RT Relapsed 2013
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationLAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER
146 Experimental Oncology 37, 146 150, 2015 (June) Exp Oncol 2015 37, 2, 146 150 LAPATINIB-BASED THERAPY FOR WOMEN WITH ADVANCED/ METASTATIC HER2 POSITIVE BREAST CANCER J. Zekri 1, 2, M. Mokhtar 3, S.M.
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Pertuzumab (Omnitarg/Perjeta ) for the first-line therapy of metastatic HER2 positive breast cancer DSD: Horizon Scanning in Oncology Nr. 31 ISSN online 2076-5940 Horizon
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
The new england journal of medicine original article Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Sandra M. Swain, M.D., José Baselga, M.D., Sung-Bae Kim, M.D., Jungsil
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationClinical Spotlight in Breast Cancer
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
More informationNew Developments in the Treatment of Recurrent Ovarian Cancer and Evolving New Therapies
New Developments in the Treatment of Recurrent Ovarian Cancer and Evolving New Therapies Alexi Wright, MD Dana-Farber Cancer Institute Harvard Medical School Email: alexi_wright@dfci.harvard.edu 617-632-3857
More informationCyclin CDK 4/6 inhibitors in breast cancer treatment. Agustí Barnadas Medical Oncology Department Hospital Sant Pau Barcelona
Cyclin CDK 4/6 inhibitors in breast cancer treatment Agustí Barnadas Medical Oncology Department Hospital Sant Pau Barcelona Agenda Cell-cycle pathway Cyclin CDK 4/6 inhibitors: Palbociclib Clinical efficacy
More informationHormonal treatment of metastatic ER+/HER2- breast cancer. Antonio Frassoldati Oncologia Clinica Ferrara
Hormonal treatment of metastatic ER+/HER2- breast cancer Antonio Frassoldati Oncologia Clinica Ferrara Treating metastatic breast cancer Only 7% of breast cancers are metastatic at the diagnosis The majority
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationMETASTATIC BREAST CANCER
METASTATIC BREAST CANCER Executive Summary Metastatic breast cancer is defined as disease beyond the breast and regional lymph nodes. Although metastatic breast cancer is generally incurable, patients
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationPositività per HER-2 nei carcinomi subcentimetrici
Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More information